25 citations
,
October 2005 in “PubMed” Keratin 19 expression in certain skin cells is temporary and not a reliable stem cell marker.
286 citations
,
August 2007 in “Journal of Clinical Investigation” Alopecia areata is an autoimmune disease where T cells attack hair follicles.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
July 2023 in “Nature Immunology” CD8+ virtual memory T cells may cause hair loss in alopecia areata.
69 citations
,
January 2013 in “Frontiers in Immunology” The FOXN1 gene is crucial for developing immune cells and preventing immune disorders.
3 citations
,
January 2023 in “JEADV Clinical Practice” IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
8 citations
,
February 2015 in “Cellular immunology” Deleting Snai2 and Snai3 causes fatal autoimmunity.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Certain immune cells, when activated by specific signals, can encourage hair growth.
54 citations
,
August 1981 in “British Journal of Dermatology” Alopecia areata is linked to reduced T cell function and auto-immunity.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
253 citations
,
December 2007 in “Journal of Investigative Dermatology” Hair follicles prevent NK cell attacks to avoid hair loss.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
November 2024 in “Malaysian Journal of Microbiology” Patients with thyroid disorders show different symptoms and antibody levels.
4 citations
,
January 2023 in “Proteomes” Tumor proteins can both promote and suppress cancer, depending on the situation.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
July 1997 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” January 2025 in “INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS”
May 2025 in “Frontiers in Immunology” Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.
January 2023 in “Discovery immunology” T cells and bacteria in the gut and skin help maintain health and protect against disease.
18 citations
,
May 2018 in “International Journal of Molecular Sciences” Human body's immune cells are more common in the layer of fat just beneath the skin than in deeper fat layers.
32 citations
,
December 2019 in “The Journal of clinical investigation/The journal of clinical investigation” A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
7 citations
,
January 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” T-cell reconstitution after thymus transplantation can cause hair whitening and loss.
21 citations
,
June 2011 in “Investigative Ophthalmology & Visual Science” Hair follicles could help develop eye treatments by studying immune responses.
7 citations
,
December 2010 in “Current Drug Therapy” Anti-complement agents could effectively treat autoimmune diseases with fewer side effects.
2 citations
,
November 1996 in “Transplantation” Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.
April 2023 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.